In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Alphatec Holdings, with a price target of $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sean Lee CFA has given his Buy rating due to a combination of factors that highlight Alphatec’s underlying business strength despite recent EOS-related setbacks. He acknowledges that first-quarter results fell short of expectations, mainly because EOS imaging revenue declined and guidance was modestly reduced, yet management still expects to meet its 2026 adjusted EBITDA and free cash flow targets, which supports confidence in the company’s profitability trajectory.
At the same time, he emphasizes that Alphatec’s core spinal surgery franchise is growing robustly, with double-digit increases in surgery revenue, case volumes, and new surgeon adoption, and additional upside from international expansion in Japan and upcoming product launches like Valence and OsteoAdapt. Combining this operating momentum with a valuation framework based on both EV-to-sales and discounted cash flow analyses, he concludes that the unchanged $24 price target remains justified and offers attractive upside, warranting a continued Buy recommendation on ATEC shares.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year.